This study aims to evaluate the impact of the neoadjuvant treatment strategy based on CPS score on the pathological complete response (pCR) rate in patients with resectable locally advanced esophageal cancer.
Diagnosis: Histologically confirmed esophageal squamous cell carcinoma (ESCC).
Stage: Resectable locally advanced ESCC (clinical stage II-III according to the AJCC/UICC 8th edition).
Age: 18-75 years old.
Performance Status: Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
Distant Metastasis: Presence of distant metastasis.
Other Malignancies: History of other malignancies within the past 5 years, except for adequately treated carcinoma in situ of the cervix, basal or squamous cell skin carcinoma, or other localized non-invasive malignancy.
Autoimmune Diseases: History of active autoimmune diseases requiring systemic treatment within the past 2 years.
Infections: Active infection requiring systemic therapy.